<i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

<div>Kaplan–Meier survival curves for (a) median progress-free survival of 9.4 months and (b) median overall survival of 15.7 months for all 17 patients.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: <i>UGT1A1</i> Polymorphism for Irinotecan Dose Escalation in Patients with <i>BRAF</i>-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 

Figure 2 | UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI 